Study Investigators Defend Stivarga’s Benefit
Executive Summary
Reporting the results of the CORRECT trial in colorectal cancer in the Lancet Nov. 22, study investigators built a case that regorafenib should be a new standard of care, despite criticism of the effect size, toxicity and cost.